Core Viewpoint - Iovance Biotherapeutics has an approved drug, Amtagvi, for treating unresectable or metastatic melanoma, but its stock has significantly declined, raising concerns among investors about its future performance [1][2]. Group 1: Stock Performance and Market Sentiment - Iovance's stock has fallen approximately 57% since the beginning of the year as of April 22, indicating a significant sell-off [5]. - The percentage of short-sellers in relation to Iovance's float has been increasing, reflecting growing skepticism about the company's future success [3]. Group 2: Financial Health and Cash Flow - Iovance is experiencing poor cash flow, which may lead to further dilution for shareholders as the company has historically relied on issuing stock to fund operations [11]. - As of the end of 2024, Iovance had cash and short-term investments totaling $323.8 million, but ongoing high cash burn could deplete this cushion over time [10]. Group 3: Future Revenue Potential - Although Amtagvi has the potential to generate $1 billion in annual revenue, this is not expected until 2030, which raises concerns about the company's ability to achieve profitability in the near term [7][12]. - Iovance reported a net loss of $372.2 million last year, highlighting the financial challenges it faces [12].

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money. So does investing in most biotech stocks. But just as one lucky lottery ticket can provide game-changing wealth, so can the right biotech stock.Iovance Biotherapeutics (IOVA 0.30%) just might be the right kind of biotech stock. The company has already achieved success. Could it even be a millionaire-maker?Iovance's opportunityTo appreciate Iovance's oppor ...

Core Insights - The biotech industry presents opportunities for significant returns in short timeframes due to clinical or regulatory advancements, with several companies projected to see substantial share price increases in the next year [1][2] Group 1: CRISPR Therapeutics - CRISPR Therapeutics is a leading gene-editing company that received approval for its therapy Casgevy, the first CRISPR-based medicine, but has struggled with sales post-approval due to complex administration [3][4] - Wall Street's average price target for CRISPR Therapeutics is $84.62, indicating a potential upside of 159%, making it a long-term investment consideration despite short-term volatility [4][5] - The company has a promising pipeline, including potential treatments for type 1 diabetes and cancer, appealing to risk-tolerant investors [5] Group 2: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer therapies using tumor-infiltrating lymphocytes and gained U.S. approval for Amtagvi to treat melanoma, achieving $164.1 million in revenue in 2024 [6][7] - The stock has a price target of $20.91, suggesting a potential upside of 543%, with upcoming regulatory approvals and a large patient base in the U.S. as catalysts for growth [7][8] - Iovance could be an attractive option for patient investors, given its innovative approach and potential for further clinical successes [9] Group 3: Regeneron - Regeneron is a well-established biotech firm facing challenges with its key product Eylea due to competition, but has a price target of $914.55, indicating a 50% upside [10] - A legal battle over Eylea's biosimilar could significantly impact share prices, while the success of Dupixent and a robust pipeline enhance its investment appeal [11][12] - The company has initiated a dividend program and continues share buybacks, reinforcing its position as a strong long-term investment [12] Group 4: Sarepta Therapeutics - Sarepta Therapeutics focuses on gene therapies for rare diseases and recently launched Elevidys, but faced a setback with a patient death linked to liver failure [13][14] - Despite the controversy, the average price target remains at $165.35, suggesting an upside of 182%, contingent on clarifying the cause of the patient's death [14][15] - Given the current uncertainty surrounding Elevidys, caution is advised for potential investors until more information is available [15]

Core Viewpoint - Iovance Biotherapeutics has innovative cancer therapies but faces challenges in market performance despite regulatory approval of its key therapy, Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics specializes in developing therapies using tumor-infiltrating lymphocytes (TILs) to target cancer cells [3]. - The company’s flagship product, Amtagvi, is a personalized treatment for melanoma that received FDA approval last year [3][4]. Market Performance - The stock has declined by 74% over the past 12 months, trading under $4 per share, which is close to its 52-week low [2]. - Analysts have a bullish outlook, with price targets ranging from $6 to $32, and an average target of $19.54 [2]. Product Details - Amtagvi takes 34 days to manufacture and is administered in specialized treatment centers, which complicates its rollout [4]. - Iovance reported $164.1 million in revenue last year and has only begun to address the 20,000 eligible melanoma patients in the U.S. [5]. Market Potential - There are an estimated 325,000 annual melanoma cases worldwide, indicating a significant market opportunity for Iovance [6]. - The company is seeking regulatory approvals in additional countries, potentially expanding its patient base by 2025 [5][8]. Future Projections - Iovance anticipates product revenue for Amtagvi to be between $450 million and $475 million in 2025 [9]. - The company has a pipeline of over a dozen programs, including trials for non-small cell lung cancer, which could serve as catalysts for growth [10]. Financial Outlook - Iovance aims to keep its cash burn under $300 million for 2025, which is below its projected revenue range [11]. - The company improved its net loss per share from $1.89 in 2023 to $1.28 in 2024, indicating progress in financial performance [12].

The time to buy quality prospects is when the rest of the market is ignoring their value.Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery. Wall Street's seemingly given up on them, looking right past everything that makes these companies -- and their stocks -- so promising.Not me, though. ...

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play. A stock that has fallen to a fraction of its price could possess significant upside if it's able to prove its doubters wrong.One stock that's down big of late is Iovance Biotherapeutics (IOVA -1.28%). Entering trading this week, the healthcare stock has lost close to 60% of its value in the past three months, and it's d ...

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

Core Insights - Iovance Biotherapeutics reported a narrower loss of 26 cents per share for Q4 2024, compared to a loss of 45 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 27 cents [1][7] - The company generated total revenues of $73.7 million in Q4 2024, significantly up from $0.5 million in the year-ago quarter, and exceeding the Zacks Consensus Estimate of $72.1 million [2][7] Revenue Breakdown - Iovance's revenue for Q4 2024 was driven by sales from two marketed drugs: Proleukin and Amtagvi [3] - Amtagvi sales reached $48.7 million in Q4 2024, up from $42.1 million in Q3 2024, although it fell short of the model estimate of $57 million [4] - Proleukin contributed $25 million in sales during the quarter, a significant increase from $0.5 million in the year-ago period, surpassing the model estimate of $15 million [5] Operating Costs - Research and development expenses decreased by 17% to $72.2 million compared to the previous year, attributed to the transition to commercial manufacturing of Amtagvi [6] - Selling, general, and administrative expenses increased by 42% to $42.5 million, driven by higher headcount and related costs [6] Full-Year Performance - For the full year 2024, Iovance reported total revenues of $164.1 million, a substantial increase from $1.2 million in the previous year [7] - The company incurred a loss of $1.28 per share for 2024, an improvement from a loss of $1.89 per share in the prior year [7] Future Guidance - Iovance reiterated its revenue guidance for 2025, expecting product revenues to be between $450 million and $475 million, with cash burn projected to be under $300 million [8] - The company anticipates significant growth in total product revenues for 2026 and beyond, with gross margins expected to exceed 70% in the coming years [9] Pipeline Updates - Regulatory applications for Amtagvi in melanoma are under review in the EU, UK, and Canada, with potential approvals expected this year [13] - Iovance is conducting a phase III study evaluating Amtagvi combined with Merck's Keytruda for frontline advanced melanoma [14] - The company is also accelerating enrollment in a phase II study for Amtagvi in post-anti-PD-1 non-small cell lung cancer, with updates expected by year-end [15]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni ...

Iovance Biotherapeutics (IOVA) Q4 2024 Earnings Call March 01, 2025 01:56 AM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporate CommunicationsFrederick Vogt - Interim CEO, President, General Counsel & Corporate SecretaryDan Kirby - Chief Commercial OfficerIgor Bilinsky - Chief Operating OfficerJean-Marc Bellemin - Chief Financial OfficerFriedrich Graf Finckenstein - Chief Medical OfficerAndrea Newkirk - Biotechnolgy Equity ResearchBenjamin Burnett - DirectorNic ...